Comparison of the Diagnostic Efficacy of 68Ga-FAPI-04 PET/MRI and 18F-FDG PET/CT in Patients With Pancreatic Cancer

2021 ◽  
Author(s):  
Zeyu Zhang ◽  
Guorong Jia ◽  
Guixia Pan ◽  
Kai Cao ◽  
Qinqin Yang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Lymph Nodes ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Multiple Sequence ◽  
Primary Tumors ◽  
Metastatic Lesions ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract PurposeTo assess the diagnostic performance of 68Ga-FAPI-04 (68Ga-FAPI) PET/MR for primary as well as metastatic lesions in pancreatic cancer patients and to compare the results with those of 18F-FDG PET/CT.MethodsProspectively, we evaluated 31 patients suspected to have pancreatic malignancy. Within one week, each patient underwent both 18F-FDG PET/CT and 68Ga-FAPI PET/MR. Comparisons of the detection abilities and the standardized uptake values (SUVs) for primary tumors, lymph nodes, as well as hepatic metastases were conducted for the two imaging approaches.ResultsTwenty-eight pancreatic cancer patients and three pancreatitis ones were enrolled. 68Ga-FAPI and 18F-FDG exhibited equivalent (100%) detection rates for primary tumors. The SUVs of primary tumors on 68Ga-FAPI PET were markedly higher than those on 18F-FDG (p < 0.05). Fifteen pancreatic cancer patients were accompanied by pancreatic parenchymal uptake, whereas 18F-FDG PET images showed parenchymal uptake in 3 patients only (53.57% vs. 10.71%, p < 0.001). The number of positive lymph nodes detected was higher for 68Ga-FAPI than for 18F-FDG PET (31 vs. 26), led to N upstaging in 27.27% (3/11) of patients, however, the difference was not statistically significant (p = 0.053). 18F-FDG PET was able to detect more liver metastases than 68Ga-FAPI, and 68Ga-FAPI uptake of metastatic tumors was significantly lower than 18F-FDG (6.13 ± 1.63 vs. 8.09 ± 1.68, p < 0.001). In larger liver metastatic lesions, 68Ga-FAPI tended to distribute around the periphery of the lesions. In addition, multiple sequence MR imaging was helpful for finding more micrometastases.Conclusion68Ga-FAPI PET demonstrated equivalent detection rate with 18F-FDG for primary tumors of pancreatic cancer, and its percentage of pancreatic parenchymal uptake caused by inflammation was higher. It might be better in the detection of suspicious lymph node metastases. The MR multiple sequence imaging of integrated PET/MR was helpful for detecting tiny liver metastases.

[68Ga]Ga-DOTA-FAPI-04 PET/CT in The Staging of Gastric Cancer: Improved Diagnostic Efficacy Confirmed By Postoperative Histopathology

2021 ◽  
Author(s):  
Rong Lin ◽  
Zefang Lin ◽  
Zhenying Chen ◽  
Shan Zheng ◽  
Jiaying Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Response To Treatment ◽  
Diagnostic Efficacy ◽  
Primary Tumors ◽  
Metastatic Lesions ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
N Staging

Abstract Purpose This study aimed to compare the diagnostic performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]-FDG PET/CT in the primary and metastatic lesions of gastric cancer. Methods Fifty-six patients with histologically proven gastric carcinomas were enrolled in this study. Each patient underwent both [18F]-FDG and [68Ga]Ga-FAPI-04 PET/CT within one week. Activity of tracer accumulation in lesions were assessed by maximum standardized uptake value (SUVmax) and TBR (lesions SUVmax/ ascending aorta SUVmean). Histological work-up including immunohistochemical staining for FAP served as a standard of reference. Results [68Ga]Ga-FAPI PET/CT is superior in detecting primary tumors both in patient-based (100% [45/45] vs. 97.8% [44/45]) and lesion-based analyses (97.8% [45/46] vs. 95.7% [44/46]), showing higher SUVmax (10.25 vs. 8.13, P = 0.004) and TBR (11.63 vs. 5.83, P < 0.001), compared with [18F]-FDG PET/CT. The specificity and positive predictive value of [68Ga]Ga-FAPI were significantly higher than that of [18F]-FDG (100.0% vs. 97.7%, P < 0.001; 100.0% vs. 57.1%, P = 0.001) in determining the lymph node (LN) metastases. [68Ga]Ga-FAPI PET/CT was superior to [18F]-FDG PET/CT in N-staging (47.1% [8/17] vs. 23.5% [4/17]), and in evaluation for LN, peritoneum and bone metastases. [68Ga]Ga-FAPI PET/CT detected positive recurrent lesions in all patients and showed more positive lesions and clearer tumor delineation. Two patients underwent follow-up [68Ga]Ga-FAPI PET/CT scans after chemotherapy, which both showed remission. Conclusions [68Ga]Ga-FAPI PET/CT can better detect primary gastric cancer and metastatic lesions in peritoneum, abdominal LNs and bone, showing high usefulness in guiding N staging. Furthermore, [68Ga]Ga-FAPI PET/CT provides more information for patients with recurrence detection and also has great potential in monitoring response to treatment.

scholarly journals A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Miaoyan Wei ◽  
Bingxin Gu ◽  
Shaoli Song ◽  
Bo Zhang ◽  
Wei Wang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
High Risk ◽  
Risk Stratification ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Resectable Pancreatic Cancer ◽  
Pet Ct ◽  
Stratification System ◽  
Fdg Pet Ct ◽  
Risk Stratification System

objectiveDespite the heterogeneous biology of pancreatic cancer, similar surveillance schemas have been used. Identifying the high recurrence risk population and conducting prompt intervention may improve prognosis and prolong overall survival.MethodsOne hundred fifty-six resectable pancreatic cancer patients who had undergone 18F-FDG PET/CT from January 2013 to December 2018 were retrospectively reviewed. The patients were categorized into a training cohort (n = 109) and a validation cohort (n = 47). LIFEx software was used to extract radiomic features from PET/CT. The risk stratification system was based on predictive factors for recurrence, and the index of prediction accuracy was used to reflect both the discrimination and calibration.ResultsOverall, seven risk factors comprising the rad-score and clinical variables that were significantly correlated with relapse were incorporated into the final risk stratification system. The 1-year recurrence-free survival differed significantly among the low-, intermediate-, and high-risk groups (85.5, 24.0, and 9.1%, respectively; p &lt; 0.0001). The C-index of the risk stratification system in the development cohort was 0.890 (95% CI, 0.835–0.945).ConclusionThe 18F-FDG PET/CT-based radiomic features and clinicopathological factors demonstrated good performance in predicting recurrence after pancreatectomy in pancreatic cancer patients, providing a strong recommendation for an adequate adjuvant therapy course in all patients. The high-risk recurrence population should proceed with closer follow-up in a clinical setting.

scholarly journals Prognostic Value of Quantitative 18F-FDG PET/CT Parameters Measured in Primary Tumors and Suspicious Lymph Nodes in Patients With Esophageal Carcinoma

2020 ◽  
Author(s):  
Francisco Tustumi ◽  
Flávio Roberto Takeda ◽  
Paulo Schiavom Duarte ◽  
David Gutiérrez Albenda ◽  
Rubens Antonio Aissar Sallum ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Nodes ◽  
Neoadjuvant Therapy ◽  
Burden Of Disease ◽  
Primary Tumor ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Primary Tumors ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Objective:Quantitative 18F-FDG PET/CT parameters have been described as prognostic indicators in esophageal cancer. The objective of this study isto evaluate the prognostic value of the maximum standardized uptake value (SUVmax), metabolic tumor value (MTV) and total lesion glycolysis (TLG) measured in the primary tumor and suspicious lymph nodes.Methods: A cohort study was performed to assess the association of SUVmax, MTV and TLG measured prior to and post neoadjuvant therapywithoverall survival (OS) of patients with esophageal cancer who received trimodal therapy. The quantitative techniques were applied in the primary tumor and suspicious lymph nodes. The OS rates were analyzed. Results: Before neoadjuvant therapy, 106 patients underwent PET/CT, and 39 patients underwent post-neoadjuvant therapy PET/CT exams. Before neoadjuvanttherapy, PET/CT showed that all the variables of the evaluated lymph nodes were statistically significant in predicting OS. Postneoadjuvanttherapy, none of the PET/CT variables of lymph nodes were related to prognosis. On the other hand, all primary tumor volumetric variables were related to overall survival. The MTV (HR: 4.66; 95% CI: 1.54-14.08) and TLG (HR: 4.86; 95% CI: 1.66-14.26) of the primary tumor post neoadjuvanttherapy and the variations in MTV (HR: 2.95; 95% CI: 1.01-3.52) and TLG (HR: 3.49; 95% CI: 1.01-3.52) of the primary tumor pre-to-post-neoadjuvanttherapy were prognostic variables. Conclusion: In patients with esophageal cancer, the burden of disease in suspicious lymph nodes and the primary tumor prior to therapy and the residual burden of disease in the primary tumor post therapy assessed by PET/CT were associated with prognosis.

Volume-based parameters on FDG-PET/CT as early predictors of disease recurrence in postmastectomy breast cancer patients with one to three positive axillary lymph nodes without adjuvant radiotherapy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1124-1124
Author(s):  
Naomi Nakajima ◽  
Masaaki Kataoka ◽  
Atsushi Nishikawa ◽  
Yoshifumi Sugawara ◽  
Shinya Sakai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

1124 Background: The indication for postmastectomy radiotherapy (PMRT) in patients with 1-3 lymph node metastases in the axilla have been controversial, despite the recommendation that PMRT should be applied. In the current study, we focused our study on volume-based parameters of pretreatment FDG-PET/CT, with the aim of investigating a measurement that could help identify high-risk populations for recurrence. Methods: We retrospectively analyzed 88 patients of breast cancer treated with modified radical mastectomy and were found to have 1-3 metastatic axillary lymph nodes between 2006 and 2010. All of them were studied with FDG-PET/CT for initial staging. We evaluated the relationship between clinicopathologic factors or PET parameters including the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) and recurrence. MTV and TLG of the primary tumor and metastatic lymph node were measured by using semi-automatically delineated volume of interest (VOI) with an isocontour threshold of 40 % of the SUVmax. The optimal cutoffs of PET parameters were determined by ROC curve analysis. Results: The median follow up duration was 39 months. Median MTV was 21.1and median TLG was 42.7. Recurrence was observed in 10 patients. The area under the ROC curve of MTV and TLG for DFS was 0.82 and 0.85, respectively. In Cox univariate analysis, estrogen receptor status (HR = 6.8, p = 0.003), triple negativity (HR = 10.4, p = 0.0008), SUVmax (HR = 71.1, p = 0.001), MTV (HR = 130.3, p < 0.0001), and TLG (HR = 234.1, p = 0.0001) were significantly related to disease free survival (DFS). The estimated 3-year DFS rates were 96.4 % for the lower MTV group (< 31.8) and 71.4% for the higher MTV group (≥ 31.8, p = 0.0005). The estimated 3-year DFS rates were 95.8 % for the lower TLG group (< 109.6) and 50.0 % for the higher TLG group (≥ 109.6, p < 0.0001). On multivariate analysis, TLG was an independent prognostic factor of DFS (HR = 8.5, p = 0.005). Conclusions: Volume-based parameters on FDG-PET/CT were significant predictors of DFS in postmastectomy breast cancer patients with 1-3 metastatic axillary lymph nodes.

scholarly journals The F-18 FDG PET/CT evaluation of the metastatic adrenal lesions of the non-lung cancer tumors compared with pathology results

2022 ◽  
Vol 53 (1) ◽  
Author(s):  
Zehra Pınar Koç ◽  
Pınar Pelin Özcan ◽  
Emel Sezer ◽  
Kadir Eser ◽  
Tuba Kara
Keyword(s):  
Lung Cancer ◽  
Adrenal Gland ◽  
Fdg Pet ◽  
Cancer Metastasis ◽  
Unknown Primary ◽  
Adrenal Tumors ◽  
Primary Tumors ◽  
Metastatic Lesions ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background The aim of this study was to evaluate the role of F-18 FDG PET/CT imaging in the diagnosis of primary and metastatic adrenal tumors that originate from non-lung cancer primary tumors. Results F-18 FDG PET/CT images of patients (8 male and 6 female; mean: 55.36 ± 16.2 years old) who attended with the diagnosis of primary or adrenal metastatic lesions other than lung cancer metastasis were evaluated in a retrospective manner. The diameter of the adrenal lesions was mean: 23.93 ± 36.6 mm with SUVmax levels of mean: 9.98 ± 7.8. The primary site of 2/3 of the patients with unknown primary was the adrenal gland, and in one of the patients primary tumor remained unknown during follow-up. Conclusions According to the results of this study, F-18 FDG PET/CT has high diagnostic performance in the diagnosis of the adrenal gland primary and metastatic lesions, which originate from non-lung cancer tumors. Further studies in the larger series are warranted.

Supraclavicular Lymph Nodes Detected by18F-FDG PET/CT in Cancer Patients: Assessment With18F-FDG PET/CT and Sonography

2012 ◽  
Vol 198 (1) ◽  
pp. 187-193 ◽  
Author(s):  
Jae-hoon Lee ◽  
Jinna Kim ◽  
Hee Jung Moon ◽  
Arthur Cho ◽  
Mijin Yun ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Supraclavicular Lymph Nodes ◽  
Pet Ct ◽  
Fdg Pet Ct

Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT

2021 ◽  
Vol 46 (5) ◽  
pp. 396-401
Author(s):  
Hanna Bernstine ◽  
Miriam Priss ◽  
Tamer Anati ◽  
Olga Turko ◽  
Miguel Gorenberg ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document